NeoGenomics stock hits 52-week low at $10.68 amid challenges

NeoGenomics Inc . (NASDAQ:NEO) stock has tumbled to a 52-week low, reaching a price level of $10.68, as the company grapples with market headwinds. According to InvestingPro data, the stock’s RSI indicates oversold territory, while analysts maintain a consensus buy recommendation with price targets ranging from $16 to $26. This latest dip underscores a challenging period for the specialized cancer diagnostics company, which has seen its stock price significantly retract by 33.74% over the past year. Despite current challenges, the company shows promising signs with revenue growth of 11.65% and expectations for profitability this year. Investors are closely monitoring the company’s performance, seeking signs of a turnaround that could stem the tide of the year-long decline. As NeoGenomics continues to navigate through a competitive landscape, the market response reflects the broader sentiment towards the company’s short-term prospects and strategic direction. Discover more insights and 8 additional ProTips for NEO on InvestingPro.

In other recent news, NeoGenomics reported its fourth-quarter 2024 earnings, showing an 11% year-over-year revenue growth to $172 million, despite a slight shortfall against expectations. The company achieved an EPS of $0.04, surpassing the forecast of $0.03, and reported a full-year revenue increase of 12% to $661 million. However, the earnings guidance for 2025, projecting an EPS range of $0.15 to $0.19, fell short of the consensus estimate of $0.20, leading to some investor concern. NeoGenomics has set its 2025 revenue guidance between $735 million and $745 million, aligning with consensus expectations.

Analysts from BTIG, Morgan Stanley (NYSE:MS), and Needham have adjusted their price targets for NeoGenomics to $17 and $18, respectively, with BTIG and Needham maintaining a Buy rating and Morgan Stanley keeping an Equalweight rating. These adjustments reflect the company’s recent revenue shortfalls and the CEO transition, but analysts remain optimistic about NeoGenomics’ fundamentals and product pipeline. The company is focusing on growth through its Next (LON:NXT) Generation Sequencing (NGS) and the anticipated launch of the NEO Pan Tracer liquid biopsy blood test panel in 2025.

NeoGenomics’ efforts to innovate, including the upcoming clinical validation of the RaDaR 1.1 minimal residual disease test, are seen as critical to its future performance. Despite the challenges, the company continues to project long-term growth, with a focus on enhancing its product offerings and expanding market reach. The firm’s strategic initiatives are expected to drive future revenue and EBITDA growth, even as it navigates the uncertainties introduced by recent leadership changes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.